|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081182 |
|
最近更新日期: Date of Last Refreshed on: |
2024-02-26 09:58:37 |
|
注册时间: Date of Registration: |
2024-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于COM-B模型2型糖尿病患者药物自我管理行为影响因素结构方程模型分析 |
|
Public title: |
Structural equation model analysis of influencing factors of drug self-management behavior in patients with type 2 diabetes mellitus based on COM-B model |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于COM-B模型2型糖尿病患者药物自我管理行为影响因素结构方程模型分析与干预研究 |
|
Scientific title: |
Structural equation model analysis and intervention research of influencing factors of drug self-management behavior in patients with type 2 diabetes mellitus based on COM-B model |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李颖 |
研究负责人: |
李颖 |
|
Applicant: |
Li Ying |
Study leader: |
Li Ying |
|
申请注册联系人电话: Applicant telephone: |
+86 18919614050 |
研究负责人电话: Study leader's telephone: |
+86 18919614050 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1807883959@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1807883959@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省合肥市梅山路117号 |
研究负责人通讯地址: |
安徽省合肥市梅山路117号 |
|
Applicant address: |
No. 117, Meishan Road, Hefei, Anhui |
Study leader's address: |
No. 117, Meishan Road, Hefei, Anhui |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
安徽中医药大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
安徽中医药大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Anhui University of Chinese Medicine? |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024AH-19 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
安徽中医药大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-01-31 00:00:00 |
||
|
伦理委员会联系人: |
徐桂琴 |
||
|
Contact Name of the ethic committee: |
Xu Guiqin |
||
|
伦理委员会联系地址: |
安徽省合肥市梅山路117号 |
||
|
Contact Address of the ethic committee: |
No. 117, Meishan Road, Hefei, Anhui |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 551 62838532 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xuqin608@163.com |
|
研究实施负责(组长)单位: |
安徽中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省合肥市梅山路117号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 117, Meishan Road, Hefei, Anhui ? |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
安徽省卫生健康委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Anhui Provincial Health Commission |
||||||||||||||||||||||
|
Target disease: |
T2DM |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
(1)开发T2DM患者药物自我管理行为的测量工具。 (2)运用以上测量工具,识别T2DM患者药物自我管理行为的关键要素和重点环节,为干预设计立下基础。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To develop a measurement tool for drug self-management behavior in T2DM patients. (2) We will use measurement tools to identify key elements and key links of drug self-management behavior in T2DM patients to lay a foundation for intervention design. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
专家:安徽省三级甲等医疗机构从事糖尿病诊疗临床医师、护师、临床药师以及卫生事业管理领域相关专家,具有相关工作经验 10 年以上;高级职称,其专业知识储备丰富、代表性较好;专家自愿并积极参与本研究。 访谈患者:安徽中医药大学第一附属医院内分泌科就诊的T2DM患者,自愿参与本研究。 问卷调查患者:以安徽地区地理特征为基础,遴选3所医疗机构能够在一定程度上代表我省医疗卫生机构T2DM患者药物自我管理能力总体情况。接受问卷调查的研究对象要求无视听障碍且能够自愿、自主完成问卷填答任务,排除认知功能障碍者、有精神病史者、不能正常沟通者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Experts: clinicians, nurses and clinical pharmacists engaged in the diagnosis and treatment of diabetes in tertiary-grade A class medical institutions in Anhui Province, and experts in the field of health management, with more than 10 years of relevant work experience; Senior professional title with rich professional knowledge reserves and good representativeness; Experts voluntarily and actively participate in this study. The interviewed patients will be T2DM patients from the Endocrinology Department of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, and will voluntarily participate in this study. Questionnaire survey patients: Based on the geographical characteristics of Anhui region, selecting three medical institutions can to some extent represent the overall drug self-management ability of T2DM patients in medical and health institutions in our province. Patients receiving the questionnairehave have no visual or auditory impairments and be able to voluntarily and independently complete questionnaire filling tasks, excluding those with cognitive impairment, a history of mental illness, and those who cannot communicate normally. |
||||||||||||||||||||||
|
排除标准: |
无 |
||||||||||||||||||||||
|
Exclusion criteria: |
None |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-11-30 00:00:00至 To 2026-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-03-01 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子数据采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic data capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |